Author of

• 14661

  +

  P2.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 225)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14668

    +

    P2.08-007 - The Efficacy and Safety of Re-Challenge Platinum plus Pemetrexed Combination Therapy for Recurrent Malignant Pleural Mesothelioma (ID 1511)

    09:30 - 09:30  |  Author(s): M. Morishita
    • Abstract

    Background:
    Malignant pleural mesothelioma (MPM) is associated with poor prognosis and 5-year survival rate was only 23.1%.Tri-modality therapy (induction chemotherapy followed by pleural pneumonectomy and adjuvant radiation), bimodality therapy (induction chemotherapy followed by pleural decortication) and chemotherapy alone viable treatment option for MPM. These initial therapies are selected according to IMIG staging, performance status, and the severity of comorbidity. These treatment options all include platinum plus pemetrexed combination therapy, which is regarded as the standard regimen for advanced MPM. However, the majority of patients showed disease relapse even when treated with multimodality strategy and the treatment options for recurrent MPM are limited. Under these findings, the current study investigated the efficacy and safety of re-challenge platinum plus pemetrexed combination therapy for recurrent MPM.
    
    Methods:
    We retrospectively reviewed 36 patients pathologically diagnosed as MPM between April 2007 and April 2015. The patients who received re-challenge platinum plus pemetrexed combination therapy as second line therapy for recurrent MPM were eligible for this study.
    
    Results:
    Of these 36 patients, 15 showed disease relapse after receiving the first treatment. 7 patients received monotherapy or best supportive care after the relapse. After all, 8 patients received re-challenge platinum plus pemetrexed combination therapy. The characteristics of the 8 patients were as follows, male/female:6/2, median age:58 years (range 49-69), performance status 0/1:2/6, epithelioid/sarcomatoid/biphasic/unknown: 6/0/1/1. Prior therapy tri-modality/bimodality/chemotherapy alone:5/0/3, treatment free interval from the completion of initial therapy <90days/≧90days; 0:8. 1 partial response and 6 stable disease were observed in 8 patients, respectively. Median progression free survival and median overall survival was 8.3 and 17.3 months, respectively. In terms of toxicity, grade 3 leukopenia was observed in one patient. No grade 3-4 thrombocytopenia was observed. In addition, grade 2 erythema was observed in one patient. Over all, the combination therapy was well tolerated.
    
    Conclusion:
    The re-challenge platinum plus pemetrexed combination was active and well tolerable for recurrent MPM.